Castle Biosciences (NASDAQ:CSTL) Director G Bradley Cole Sells 7,403 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) Director G Bradley Cole sold 7,403 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $28.47, for a total value of $210,763.41. Following the completion of the sale, the director directly owned 19,309 shares of the company’s stock, valued at approximately $549,727.23. The trade was a 27.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Castle Biosciences Stock Down 0.4%

Shares of NASDAQ:CSTL traded down $0.10 during midday trading on Monday, hitting $27.02. The stock had a trading volume of 335,732 shares, compared to its average volume of 439,870. The company has a market cap of $803.33 million, a P/E ratio of -31.79 and a beta of 1.09. Castle Biosciences, Inc. has a 12 month low of $14.59 and a 12 month high of $44.28. The business’s 50-day simple moving average is $35.92 and its 200-day simple moving average is $31.57. The company has a quick ratio of 5.11, a current ratio of 5.26 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.15. The firm had revenue of $81.88 million for the quarter, compared to analyst estimates of $81.19 million. Castle Biosciences had a negative net margin of 7.02% and a negative return on equity of 0.89%. On average, sell-side analysts forecast that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Castle Biosciences

A number of large investors have recently made changes to their positions in the company. Federated Hermes Inc. bought a new stake in Castle Biosciences in the 4th quarter valued at $26,000. Farther Finance Advisors LLC increased its position in Castle Biosciences by 139,100.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock worth $32,000 after buying an additional 1,391 shares during the period. State of Alaska Department of Revenue acquired a new stake in shares of Castle Biosciences during the third quarter worth $35,000. Kemnay Advisory Services Inc. bought a new stake in shares of Castle Biosciences in the fourth quarter valued at about $35,000. Finally, CWM LLC grew its stake in shares of Castle Biosciences by 80.6% in the third quarter. CWM LLC now owns 1,911 shares of the company’s stock valued at $44,000 after acquiring an additional 853 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

CSTL has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Castle Biosciences in a research note on Monday, December 29th. Morgan Stanley raised Castle Biosciences to a “buy” rating in a research report on Monday, March 2nd. KeyCorp reaffirmed an “overweight” rating and issued a $50.00 price objective on shares of Castle Biosciences in a research report on Thursday, January 29th. BTIG Research lifted their target price on Castle Biosciences from $38.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Finally, Zacks Research lowered Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, March 2nd. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $47.57.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.